The antiadipogenic effect of the pentacyclic triterpenoid isoarborinol is mediated by LKB1-AMPK activation
Arcos-Reyes Y., Rivera G., Marchat LA., Salas-Benito J., Mandujano-Lázaro G., Monzón-Gualito M.
Animal Study, published in PLoS One (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- PLoS One (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40901838
- PMCID
- PMC12407445
- DOI
- 10.1371/journal.pone.0330860
Abstract (original English)
Obesity and overweight are two highly prevalent conditions worldwide, which can lead to death or produce chronic and degenerative diseases. The search for alternative therapies to control these morbidities can involve the study of metabolites obtained from plants. Particularly, pentacyclic triterpenes produce an antiadipogenic effect by affecting the expression of master regulators of adipogenesis and their signaling pathways, including LKB1-AMPK pathway. In this work, we evaluated the effect of the pentacyclic triterpene isoarborinol on adipogenesis in 3T3-L1 cells. This molecule inhibits differentiation and decreases lipid accumulation during cell differentiation in a dose-dependent manner, deregulates the expression of C/EBPβ, C/EBPδ, C/EBPα, PPARγ and SREBP-1C, causes an increase in the phosphorylation of LKB1 and AMPK, as well as a down regulation of the lipogenic factors ACC1, FAS and FABP4. These findings show that the antiadipogenic effect of isoarborinol is associated with the activation of LKB1-AMPK, leading to changes in the expression of master regulators of adipogenesis and lipogenic factors.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.